Teva Pharmaceutical Industries Ltd - Company Profile
Powered by 
All the data and insights you need on Teva Pharmaceutical Industries Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Teva Pharmaceutical Industries Ltd Strategy Report
- Understand Teva Pharmaceutical Industries Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Teva Pharmaceutical Industries Ltd (Teva) discovers, develops, manufactures, and commercializes generic and specialty medicines. The company provides specialty medicines to treat disorders of the central nervous system (CNS), cancer, respiratory, dermatology, women’s health, and other disease conditions. It offers generic medicines in various dosage forms including capsules, tablets, injectables, liquids, inhalants, creams, and ointments. Teva also provides over-the-counter (OTC) products, besides active pharmaceutical ingredients (APIs). It also focuses on developing generic drugs. The company conducts its worldwide operations through a network of subsidiaries in regions such as North America, Europe, and international markets. Teva is headquartered in Tel Aviv, Israel.
Headquarters
Israel
Address
124 Dvora HaNevi'a St., Tel Aviv, 6944020
Website
www.tevapharm.com
Telephone
972 3 9148213
No of Employees
35,001
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
TEVA (TLV)
Revenue (2022)
$15.8B
6.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
77.1%
(2022 vs 2021)
Market Cap*
$15.7B
Net Profit Margin (2022)
XYZ
78.5%
(2022 vs 2021)
* As of and is in US$
Teva Pharmaceutical Industries Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Innovative Medicines: | Contract Manufacturing | Apriso |
| Central Nervous System | Out-licensing Generic Pharmaceuticals | NuvaRing |
| Respiratory | AndroGel | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In April, the company entered into a clinical collaboration agreement with Launch Therapeutics Inc and Abingworth to accelerate the clinical research program of Teva’s ICS-SABA (TEV-248). |
| 2024 | Contracts/Agreements | In February, the company's subsidiary Teva Pharmaceutical Investments Singapore Pte Ltd (TPIS), entered into a partnership with Jiangsu Nhwa Pharmaceutical Co Ltd (Nhwa) for the marketing and distribution of Teva’s AUSTEDO (deutetrabenazine). |
| 2024 | Regulatory Approval | In February, the company announced the approval of SIMLANDI (adalimumab-ryvk) injection from the US Food and Drug Administration (FDA). |
Competitor Comparison
| Key Parameters | Teva Pharmaceutical Industries Ltd | Merck & Co Inc | Pfizer Inc | AstraZeneca Plc | Bristol-Myers Squibb Co |
|---|---|---|---|---|---|
| Headquarters | Israel | United States of America | United States of America | United Kingdom | United States of America |
| City | Tel Aviv | Kenilworth | New York | Cambridge | Princeton |
| State/Province | Tel Aviv | New Jersey | New York | England | New Jersey |
| No. of Employees | 35,001 | 72,000 | 88,000 | 89,900 | 34,100 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Sol J. Barer, Ph.D. | Chairman | Executive Board | 2017 | 76 |
| Richard D. Francis | Chief Executive Officer; Director; President | Executive Board | 2023 | - |
| Eli Kalif | Executive Vice President; Chief Financial Officer | Senior Management | 2019 | 51 |
| David McAvoy | Executive Vice President; Chief Legal Officer | Senior Management | 2024 | - |
| Eric A. Hughes, MD | Chief Medical Officer; Executive Vice President - Global R&D | Senior Management | 2022 | 54 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward